[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371812-105":59,"doc-detail-371812-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","allele-specific-hla-loh-in-solid-tumors-distinct-patterns-by-tumor-type-and-potential-prognostic-relevance","Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance","","T-cell receptor (TCR) therapies depend on antigen fragments processed and presented by specific HLA molecules, making HLA loss of heterozygosity (LOH) a possible resistance mechanism. Using a real-world dataset of 78,418 cases, allele-specific HLA LOH appeared in under 10% of cancer patients and rose modestly with KRAS or TP53 neoantigen driver mutations. Integrating clinical outcomes with an orthogonal dataset showed distinct overall-survival impacts in colorectal cancer and non-small cell lung cancer cohorts, including worse survival for CRC with A*02:01-specific LOH and a survival trend in NSCLC, supporting TCR-based immunotherapy optimization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/allele-specific-hla-loh-in-solid-tumors-distinct-patterns-by-tumor-type-and-potential-prognostic-relevance/371812/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/allele-specific-hla-loh-in-solid-tumors-distinct-patterns-by-tumor-type-and-potential-prognostic-relevance/371812.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main focus regarding immunotherapy resistance?","Question",{"text":112,"@type":113},"The study examines allele-specific HLA loss of heterozygosity (LOH) as a potential resistance mechanism for HLA-restricted, TCR-based cancer immunotherapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How frequently does allele-specific HLA LOH occur across cancer patients?",{"text":117,"@type":113},"Using a real-world dataset of 78,418 cases, allele-specific HLA LOH was observed at a relatively low frequency, under 10%, across patients with cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"How does allele-specific HLA LOH relate to survival outcomes in different cancers?",{"text":121,"@type":113},"An orthogonal dataset linked allele-specific HLA LOH to distinct overall-survival effects, including worse survival in colorectal cancer for A*02:01-specific LOH and a different trend in non-small cell lung cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371812,1790990803,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Open access Short report  \n Allele-specific HLA LOH in solid  \ntumors: distinct patterns by tumor type and potential prognostic relevance  \nTomasz Sewastianik  ,1 Christian Roy  ,1 Michael V Gormally  ,2 Meagan Montesion,3 Patrick Halvey,1 Aastha Jindal,1 Hubert Lam,1 Adam Schoenfeld  ,2 Christopher A Klebanoff,2 Gregory J Opiteck  ,1 Dirk Nagorsen  1  \nTo cite: Sewastianik T, Roy C, Gormally MV, et al. Allelespecific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance. Journal for ImmunoTherapy of Cancer 2025;13:e012435 . doi:10 . 1136/ jitc-2025-012435  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012435](jitc-2025-012435)) .  \nAccepted 01 August 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Affini-T Therapeutics Inc, Watertown, Massachusetts, USA 2Memorial Sloan Kettering Cancer Center, New York, New York, USA  \n3Foundation Medicine Inc, Cambridge, Massachusetts, USA  \nCorrespondence to  \nDr Tomasz Sewastianik;  \n[tomasz.sewastianik@gmail.com](tomasz.sewastianik@gmail.com)  \nABSTRACT  \nT-cell receptors (TCRs) recognize antigens derived from fragments of somatically expressed proteins that are degraded by the proteasome and presented by specific human leukocyte antigen (HLA) molecules. Recent therapeutic advances using the TCR as a tumor-targeting moiety have focused attention on HLA loss of heterozygosity (LOH) as a potential resistance mechanism. Allele-specific LOH, rather than alleleagnostic, is particularly pertinent, but rarely evaluated.  \nUsing a real-world dataset comprising 78,418 cases, we demonstrate that allele-specific LOH occurs at a relatively low frequency (\u003C10%) across all patients with cancer. We observed a modest increase in allele-specific HLA LOH in cancers harboring associated neoantigen driver mutations (eg, KRAS or TP53 mutations), but the overall frequency remained consistently low. Furthermore, using an orthogonal dataset, we integrated clinical outcomes with HLA LOH and identified distinct impacts on overall survival in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) cohorts. For instance, A*02:01-specific LOH was linked to worse survival in CRC (HR 0 .5355, 95% CI 0.2991 to 0 .9589, p=0 .0094) but showed a trend toward improved survival in NSCLC (HR 1 .249, 95% CI 0.7778 to 2 .005) . These findings underscore the relevance of allele-specific HLA LOH assessments and reveal nuanced differences in its clinical implications, which should be accounted for in the optimization of TCR-based immunotherapies.  \nBACKGROUND  \nImmunotherapies have transformed cancer treatment, but unpredictability and limited durability of clinical response remain significant challenges to curing more solid tumors.1 Human leukocyte antigen (HLA)-restricted immunotherapies that use the exquisite sensitivity of the T-cell receptor (TCR) to home to antigens presented by the major histocompatibility complex (MHC) on the tumor cell surface have shown particular promise (including US Food and Drug Administration approval of the first-in-class adoptive TCRT-cell therapy afami-cel in 2024) .2–4 However, it remains unclear whether alterations in  \nepitope processing and HLA presentation pathways may affect the efficacy of these HLA-restricted approaches.5 6  \nThe MHC class I system is comprised of three classical genes (HLA-A, HLA-B, and HLA-C) that are among the most polymorphic in the human genome. Each individual’s unique complement of these alleles is essential for presenting foreign antigens (including tumor neoantigens derived from somatic mutations) to cytotoxic T cells that then recognize and eliminate cells expressing them. Genetic loss of either of the two HLA alleles at a given locus, known as HLA loss of hetero","cbCaia48MdvaNqAS","https://ap.wps.com/l/cbCaia48MdvaNqAS","pdf",1258272,"English","# Abstract\n# Background","[{\"question\":\"What is the study’s main focus regarding immunotherapy resistance?\",\"answer\":\"The study examines allele-specific HLA loss of heterozygosity (LOH) as a potential resistance mechanism for HLA-restricted, TCR-based cancer immunotherapies.\"},{\"question\":\"How frequently does allele-specific HLA LOH occur across cancer patients?\",\"answer\":\"Using a real-world dataset of 78,418 cases, allele-specific HLA LOH was observed at a relatively low frequency, under 10%, across patients with cancer.\"},{\"question\":\"How does allele-specific HLA LOH relate to survival outcomes in different cancers?\",\"answer\":\"An orthogonal dataset linked allele-specific HLA LOH to distinct overall-survival effects, including worse survival in colorectal cancer for A*02:01-specific LOH and a different trend in non-small cell lung cancer.\"}]","Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance | PDF",1790192925,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1aa989eec99284941be1a18e3c80d945.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15ee31d5e849890a7b4aa835a48c6ff0.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee2b61711c0f9df4d7c7fde6c91022f6.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92abe56a29f36ca1bbe5ef869f928801.webp",980,1306]